Spots Global Cancer Trial Database for A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
Official Title: A Phase I Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
Study ID: NCT02507544
Interventions
Study Description
Brief Summary: TRX-818 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. TRX-818 is a potent anti-cancer agent in numerous human cancer cell lines. The objectives of this study are to determine the safety profile of TRX-818 including identification of dose limiting toxicity (DLT) and maximum tolerated dose (MTD) and determine the recommended dose and regimen(s) to initiate Phase 2.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
START Midwest, Grand Rapids, Michigan, United States
South Texas Accelerated Research Therapeutics, LLC (START), San Antonio, Texas, United States
Contact Details
Name: Anthony W Tolcher, M.D., FRCP(C)
Affiliation: South Texas Accelerated Research Therapeutics, LLC (START)
Role: PRINCIPAL_INVESTIGATOR
Name: Nehal Lakhani, M.D., Ph.D.
Affiliation: START Midwest
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
